Clinical Trial Update: A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ABY-035 for efficacy, tolerability, and safety in active psoriatic arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• ABY-035 (ABY-035)

Snippet

Sponsor: ACELYRIN Inc. | Conditions: Psoriatic Arthritis | Phase 2 | Status: COMPLETED